Today

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). We compared iza-bren with platinum-based chemotherapy in participants with EGFR-mutated advanced non-squamous…

Why it mattersA bispecific EGFR-HER3 ADC beat platinum chemotherapy after third-generation TKI failure in EGFR-mutated NSCLC, offering a targeted option where chemotherapy is the current default.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in patients with EGFR-mutated advanced NSCLC that had progressed after EGFR…

Why it mattersIf this HER3 ADC beats chemotherapy after TKI failure, it gives your EGFR-mutated patients a new option before or alongside platinum doublets.

Laparoscopic Versus Open Liver Resection for Colorectal Liver Metastases : An Individual Participant Data Meta-analysis of Four Randomized Clinical Trials.

Randomized clinical trials (RCTs) have compared laparoscopic liver resection (LLR) and open liver resection (OLR) for colorectal liver metastases (CRLM); however, long-term outcomes and subgroup effects have not been comprehensively evaluated. PURPOSE: To compare postoperative and long-term oncologic outcomes after LLR versus OLR for CRLM using individual participant data from RCTs.…

Why it mattersPooled RCT data on laparoscopic versus open resection for CRLM gives you long-term oncologic and subgroup evidence to counsel patients on the minimally invasive approach.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Therapeutic options for patients with endometrial cancer who progress after platinum-based chemotherapy and immunotherapy are scarce, and prognosis is poor. Sacituzumab tirumotecan (sac-TMT) is a trophoblast cell-surface antigen 2-directed antibody-drug conjugate with a unique, bifunctional linker that maximises delivery of a belotecan-derived topoisomerase I inhibitor payload to…

Why it mattersIf sac-TMT beats physician's choice after platinum and immunotherapy, it gives your post-progression endometrial cancer patients a TROP2-directed option where few exist.

Obesity and Cancer Risk in Young Adults in Korea : A Nationwide Health Screening Cohort Study.

Obesity and early-onset cancer are both increasing among young adults, yet evidence remains limited. OBJECTIVE: To assess associations between obesity and early-onset cancer risk in young adults. DESIGN: Nationwide population-based cohort study. SETTING: Korean National Health Insurance Service database, 2009 to 2021. PATIENTS: 6 313 338 adults aged 20 to 39 years without prior…

Why it mattersReinforces weight as a modifiable cancer risk factor in patients under 40, supporting earlier counselling on BMI even in young, otherwise healthy adults.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Patients with heavily pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer have few treatment options. Izalontamab brengitecan (iza-bren) is a first-in-class, epidermal growth factor receptor and HER3 bispecific antibody-drug conjugate that contains a potent topoisomerase I inhibitor payload (Ed-04). The aim of…

Why it mattersA first-in-class EGFR/HER3 bispecific ADC offers a new mechanism for heavily pretreated HR+/HER2- disease, where endocrine and chemotherapy options are largely exhausted.

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvant chemoimmunotherapy guided by multidisciplinary team assessments during the…

Why it mattersAdds a perioperative durvalumab pathway for borderline-resectable NSCLC, with MDT triage deciding who proceeds to surgery versus CRT plus consolidation.

Impact of Unrestricted Artificial Intelligence Scribe Deployment in a Single Health System on Clinician Workload and Productivity : A Quality Improvement Study.

Ambient artificial intelligence (AI) medical scribes may reduce documentation burden and clinician burnout. Whether use intensity drives benefits remains uncertain. OBJECTIVE: To evaluate the association between AI scribe (Heidi) enrollment and documentation burden and whether changes differ by use intensity. DESIGN: Retrospective quality improvement study using an interrupted time…

Why it mattersAmbient AI scribes cut documentation time, but the benefit tracked with how much clinicians actually used them — adoption, not licensing, is what buys you time back.